Home Tags Brentuximab Vedotin

Tag: Brentuximab Vedotin

U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...

The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Market Growth, Demand, Trends and Share of Antibody-drug Conjugates (2017 –...

A report published by Persistence Market Research (PMR), a U.S.-based full-service market intelligence firm specializing in syndicated research, shows that the global market for...

Positive Results from Phase III ECHELON-1 Trial Evaluating Brentuximab Vedotin in...

ECHELON-1, a randomized, multicenter, phase III clinical trial evaluating brentiximab vedotin (Adcetris®) as part of a combination chemotherapy regimen in 1,334 patients with advanced...

NICE Issues Technology Appraisal Guidance for Brentuximab Vedotin in CD30-Positive Hodgkin...

Earlier this year, NICE, the United Kingdom's National Institute for Health and Care Excellence has issued a new Technology Appraisal Guidance for brentuximab vedotin (Adcetris®,...

Seattle Genetics Submits Supplemental Biologics License Application Brentuximab Vedotin in Cutaneous...

Seattle Genetics has submitted a supplemental Biologics License Application or BLA to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin (Adcetris®) for...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

Updates from the 14th International Conference on Malignant Lymphoma (ICML)

Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Combination of Brentuximab Vedotin and Nivolumab Shows 85% Objective Response Rate...

An updated interim analysis from the ongoing phase I/II clinical trial evaluating  brentuximab vedotin (Adcetris®; Seattle Gentics) and nivolumab (Opdivo®; Bristol-Myers Squibb) in relapsed...
Featured Image: Journal + glasses. Courtesy: © 2017 - 2019. Fotolia. Used with permission.

The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...

Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®)  in patients with cutaneous T-cell lymphoma (CTCL) were published in the...